4 recruiting, 2 not yet recruiting. 6 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Not yet recruiting 2 |
| Phase 1 | 4 | Recruiting 3, Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Systemic Lupus Erthematosus: new trials by email Literature Review of Systemic Lupus Erthematosus trials Research Report on Systemic Lupus Erthematosus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus Ivarmacitinib Sulfate Tablets, Prednisone Acetate Tablets - Systemic Lupus Erthematosus | Phase 2 / Phase 3 | Not yet recruiting | Chinese SLE Treatment And Research Group | 294 | 2026-10-15 | 2026-09-11 |
| A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) Budoprutug - Systemic Lupus Erthematosus | Phase 1 / Phase 2 | Recruiting | Climb Bio, Inc. | 30 | 2026-06-30 | 2026-10-20 |
| A Study of GR1803 in Systemic Lupus Erythematosus GR1803 injection - Systemic Lupus Erthematosus, Auto Immune Disease | Phase 1 / Phase 2 | Recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 44 | 2026-02-02 | 2026-03-10 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| COVID-19 Booster and IIV Schedule in Immunocompromised Hosts Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1 - COVID 19, Influenza | Phase 2 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 660 | 2024-11-20 | 2026-10-26 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Myositis (2) · Scleroderma, Systemic (2) · Sjogren's Syndrome (2) · Antiphospholipid Syndrome (1) · Arthritis, Rheumatoid (1) · COVID-19 (1) · Inflammatory Bowel Diseases (1) · Influenza, Human (1) · Lupus Erythematosus, Systemic (1)
Autoimmune Diseases (4) · Connective Tissue Diseases (4) · Immune System Diseases (4) · Skin and Connective Tissue Diseases (4) · Arthritis (3) · Joint Diseases (3) · Musculoskeletal Diseases (3) · Rheumatic Diseases (3) · Arthritis, Rheumatoid (2) · Cardiovascular Diseases (2) · Dry Eye Syndromes (2) · Eye Diseases (2) · Lacrimal Apparatus Diseases (2) · Mouth Diseases (2) · Muscular Diseases (2)
Prednisone (1) · ivarmacitinib (1)
Peking University Third Hospital (2) · Chinese SLE Treatment And Research Group (1) · Climb Bio, Inc. (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1)
China (4) · Canada (1)
2025 (1)